Summary:
CEOs of Septerna, Upstream Bio and Actuate share insights on IPO preparation, timing, team building, and market navigation in challenging biotech investment climate of 2024-2025.
Summary:
Newleos Therapeutics debuts with four clinical-stage brain drugs from Roche, focusing on anxiety and substance use disorders. Goldman Sachs leads funding with Novo Holdings support.
Summary:
Rising investment in I&I sector drives novel drug development and M&A activity, targeting diseases like IBD and atopic dermatitis with projected market value of $257B by 2032.
Summary:
Biogen partners with Stoke Therapeutics on Dravet syndrome drug zorevunersen in $165M upfront deal, with potential for $385M more, sharing global development rights.
Summary:
Arcus Biosciences’ casdatifan demonstrates 33% response rate and 9.7-month progression-free survival in Phase I/Ib trial, potentially rivaling Merck’s Welireg.
